Rankings
▼
Calendar
TARS Q2 2024 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
TARS
Tarsus Pharmaceuticals, Inc.
$3B
Q2 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$41M
Gross Profit
$38M
92.6% margin
Operating Income
-$33M
-81.6% margin
Net Income
-$33M
-81.6% margin
EPS (Diluted)
$-0.88
QoQ Revenue Growth
+47.8%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$15M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$377M
Total Liabilities
$125M
Stockholders' Equity
$252M
Cash & Equivalents
$181M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$41M
$0
—
Gross Profit
$38M
-$316,000
+12064.9%
Operating Income
-$33M
-$33M
-1.5%
Net Income
-$33M
-$31M
-5.9%
Revenue Segments
Product
$41M
100%
← FY 2024
All Quarters
Q3 2024 →